Bioprocess Engineering in
Plasma-Derived Biopharmaceuticals
Nojin Biopharma, as a pioneer in the biological pharmaceutical industry, integrates Class A cleanroom quality control with advanced molecular separation technologies, committing to elevate the national capacity of human plasma-derived biopharmaceuticals.
The largest nominal blood plasma fractionation capacity in the country, powered by modern phase-separation technology.
Production of life-saving immunoglobulins, albumin, and coagulation factors relying on indigenous biotechnology.
Continuous development of purification processes in collaboration with national biopharma experts and medical doctors.
Implementation of advanced nanofiltration methods and multi-step pathogen inactivation.
Nojin Biological Products Portfolio
Scientific monographs, clinical data, and specifications of human plasma-derived biopharmaceuticals.
ALBUJINE® 20%
Human Albumin 20% - Solution Vial 50 ml
Albumin is the most abundant plasma protein, responsible for maintaining 70% to 80% of the intravascular colloid osmotic pressure.
Main Indications
Indicated for volume expansion and maintenance of cardiac output in the treatment of hypovolemic shock.
IMMUNOJINE® 2500 mg
Immune Globulin Intravenous (IVIG) - 50 ml Injection
This biological product contains intact polyclonal antibodies extracted from healthy human plasma providing passive immunity.
Main Indications
Used as replacement therapy in Primary and Secondary Immunodeficiency syndromes, and autoimmune conditions.
Advancing Self-Sufficiency in Biopharmaceutical Production
Our focus is on patient safety, high formulation standards, and continuous research and development.
Scientific Innovation
Utilizing advanced bioprocesses for recombinant drug formulation.
National Self-Sufficiency
Reducing international dependency in human plasma-derived biopharmaceuticals production.
Global GMP Standards
Adherence to the strictest World Health Organization guidelines in cleanrooms.
Latest Scientific Achievements
The Role of Nanotechnology in Enhancing the Stability of Injectable Biological Formulations
Injectable biological formulations are highly sensitive to environmental changes and shear forces. Utilizing nano-systems can improve the physicochemical stability of active proteins during storage.
Development of New Plasma-Derived Pharmaceutical Product Portfolio This Year
Nojin Zist Pharmed's pharmaceutical portfolio is developing new clinical treatment options in line with maximizing the coverage of the country's therapeutic needs.
Review of GMP Standard Requirements in Cold Chain Storage of Biological Products
Compliance with Good Manufacturing Practice (GMP) legal requirements in the storage and distribution sector guarantees maintaining the safety and efficacy of biological products.
Localization of Advanced Plasma Fractionation Process; A Vital Step in the Country’s Pharmaceutical Self-Sufficiency
Achieving technological independence in the human blood plasma fractionation chain is one of the country's strategic goals in the field of pharmaceutical biotechnology. In this scientific monograph, we review the achievements of Nojin's R&D department in localizing advanced membrane separation methods.
Have a Question? Find the Answer with
Our Scientific Experts
In this section, we have endeavored to answer your frequently asked questions about the plasma fractionation process, GMP biosafety requirements, and strategic cold chain logistics in the most scientific manner.
Dr. Ali Mousavi
Director of Scientific Support & Biotechnology
Scientific Support Portal
Our scientific support team is ready to answer specialized questions on pharmacodynamics and dosage for clinics and hospitals.
Human plasma enters the production chain of plasma-derived drugs under advanced screening processes, enrichment, and continuous genetic monitoring to achieve maximum purity and safe biological efficacy.
All production processes are conducted under the strict supervision of the Food and Drug Administration (IFDA) and in compliance with the latest World Health Organization (WHO-GMP) protocols to guarantee product safety.
Requests for single-prescription biological medications can be tracked through Nojin’s integrated supply system following approval by the company’s medical and scientific committee.
Yes, our Research and Development (R&D) department maintains deep ties with top-tier national medical universities in line with localizing modern plasma fractionation technologies.
All pharmaceutical vials possess a unique tracking code (UID) connected to the FDA TTAC system, which instantly verifies the product’s authenticity.
We utilize a specialized logistics fleet equipped with smart monitoring and electronic temperature logging to ensure products reach medical centers precisely between 2 and 8 degrees Celsius without any fluctuation.